Financials data is unavailable for this security.
View more
Year on year Johnson & Johnson grew revenues 6.46% from 79.99bn to 85.16bn while net income improved 95.94% from 17.94bn to 35.15bn.
| Gross margin | 69.16% |
|---|---|
| Net profit margin | 16.84% |
| Operating margin | 20.10% |
| Return on assets | 8.58% |
|---|---|
| Return on equity | 20.89% |
| Return on investment | 11.90% |
More ▼
Cash flow in USDView more
In 2023, Johnson & Johnson increased its cash reserves by 54.73%, or 7.73bn. The company earned 22.79bn from its operations for a Cash Flow Margin of 26.76%. In addition the company generated 878.00m cash from investing, though they paid out 15.83bn more in financing than they received.
| Cash flow per share | 9.08 |
|---|---|
| Price/Cash flow per share | 16.72 |
| Book value per share | 29.14 |
|---|---|
| Tangible book value per share | -5.87 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.03 |
|---|---|
| Quick ratio | 0.7853 |
| Total debt/total equity | 0.5096 |
|---|---|
| Total debt/total capital | 0.3376 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 5.62% while earnings per share excluding extraordinary items fell by -15.30%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.61% |
|---|---|
| Div growth rate (5 year) | 5.83% |
| Payout ratio (TTM) | 79.26% |
| EPS growth(5 years) | -1.47 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 27.66 |
More ▼
